Immunogen Inc
Related Articles
What Analysts Recommend for IMGN after Its Q1 Results
On May 15, Immunogen (IMGN) issued a press release announcing mature data from its FORWARD II expansion cohort.
Why Immunogen Was Down by More than 30% on May 15
On May 15, Immunogen (IMGN) issued a press release announcing the FDA’s recommendation to conduct a new Phase 3 trial.
Why ImmunoGen Tanked on Friday
On March 1, ImmunoGen (IMGN) closed at $2.51, 46.82% lower than its previous closing price.
How Has Cara Therapeutics’ 2018 Performance Shaken Out?
Cara Therapeutics (CARA) is a clinical-stage biotechnology company developing new chemical entities for managing pain and pruritus.
Behind Jazz’s Strategic Collaboration with ImmunoGen
In August 2017, Jazz Pharmaceuticals (JAZZ) and ImmunoGen (IMGN) entered into a strategic collaboration and option agreement.
Immunogen Topped the Small-Cap Stocks with High Volumes
Immunogen rose by 7.2% as of November 25, 2015. The stock rose on the high trading volume. It closed at $13.76. It passed the 100-day moving average price.
XBI Contradicted the Market, Agios Rose by 8.3%
The SPDR S&P Biotech ETF (XBI) rose 2% for the day. It was one of the top gainers among the biotech ETFs. Nearly 80% of XBI’s holdings gave a positive return.
Ultragenyx: A Top Loser in the Biotechnology Subgroup
Ultragenyx Pharmaceutical (RARE) fell by 8.2% due to profit-booking. It had a high trading volume of ~700,000 shares. The stock closed at $86.99.